Aptic Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.50 M
as on 03-01-2025
- Paid Up Capital ₹ 0.10 M
as on 03-01-2025
- Company Age 13 Year, 2 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 8.03 M
as on 03-01-2025
- Revenue 12.95%
(FY 2021)
- Profit 146.84%
(FY 2021)
- Ebitda 98.52%
(FY 2021)
- Net Worth 2.35%
(FY 2021)
- Total Assets 47.02%
(FY 2021)
About Aptic Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.50 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹8.03 M.
Abin Thomas, Nimy Thomas, and Rajkumar Shunmughan serve as directors at the Company.
- CIN/LLPIN
U24233KL2011PTC029791
- Company No.
029791
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
11 Nov 2011
- Date of AGM
28 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ernakulam
Industry
Company Details
- Location
Thrissur, Kerala, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Aptic Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Abin Thomas  | Managing Director | 11-Nov-2011 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Nimy Thomas | Director | 16-Aug-2013 | Current |
| Rajkumar Shunmughan | Director | 26-Apr-2023 | Current |
Financial Performance of Aptic Pharmaceuticals.
Aptic Pharmaceuticals Private Limited, for the financial year ended 2021, experienced significant growth in revenue, with a 12.95% increase. The company also saw a substantial improvement in profitability, with a 146.84% increase in profit. The company's net worth moved up by a moderate rise of 2.35%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Aptic Pharmaceuticals?
In 2021, Aptic Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 26 Dec 2024 | ₹5.00 M | Open |
State Bank Of India Creation Date: 10 Mar 2014 | ₹3.03 M | Open |
How Many Employees Work at Aptic Pharmaceuticals?
Unlock and access historical data on people associated with Aptic Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Aptic Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Aptic Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
